Definium Therapeutics (NASDAQ:DFTX) Stock: Insider Brandi Roberts Sells 3,377 Shares

Definium Therapeutics, Inc. (NASDAQ:DFTX) CFO Brandi Roberts sold 3,377 shares of the company’s stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer owned 394,528 shares of the company’s stock, valued at $14,427,888.96. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Trading Down 0.5%

NASDAQ DFTX traded down $0.20 during trading hours on Tuesday, hitting $38.21. 1,967,182 shares of the company’s stock were exchanged, compared to its average volume of 2,245,960. The business’s 50 day moving average is $41.37 and its 200-day moving average is $32.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics, Inc. has a 12-month low of $10.46 and a 12-month high of $49.70. The firm has a market capitalization of $5.13 billion, a P/E ratio of -11.14 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, analysts anticipate that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DFTX. Avoro Capital Advisors LLC purchased a new position in shares of Definium Therapeutics in the 4th quarter valued at $66,950,000. Wellington Management Group LLP purchased a new stake in Definium Therapeutics during the 2nd quarter worth $138,755,000. Bank of New York Mellon Corp increased its holdings in Definium Therapeutics by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after purchasing an additional 24,349 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in Definium Therapeutics in the 2nd quarter valued at $6,992,000. Finally, Platinum Investment Management Ltd. purchased a new position in Definium Therapeutics in the fourth quarter valued at about $937,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on DFTX. Maxim Group set a $55.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 14th. Stifel Nicolaus lifted their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a report on Monday, September 14th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Definium Therapeutics in a research report on Friday, September 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Definium Therapeutics presently has an average rating of “Buy” and an average target price of $64.88.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.